NasdaqCM - Nasdaq Real Time Price • USD
Corcept Therapeutics Incorporated (CORT)
As of 11:10 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | 0.22 | 0.25 | 1.02 | 1.28 |
| Low Estimate | 0.19 | 0.2 | 0.84 | 0.97 |
| High Estimate | 0.26 | 0.31 | 1.15 | 1.48 |
| Year Ago EPS | 0.14 | 0.25 | 0.94 | 1.02 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | 141.2M | 150.69M | 610.64M | 665.77M |
| Low Estimate | 136M | 146.44M | 600.14M | 635M |
| High Estimate | 145.84M | 154.44M | 621.95M | 707.97M |
| Year Ago Sales | 105.65M | 109.69M | 482.38M | 610.64M |
| Sales Growth (year/est) | 33.60% | 37.40% | 26.60% | 9.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.19 | 0.15 | 0.22 | 0.26 |
| EPS Actual | 0.14 | 0.25 | 0.28 | 0.28 |
| Difference | -0.05 | 0.1 | 0.06 | 0.02 |
| Surprise % | -26.30% | 66.70% | 27.30% | 7.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.22 | 0.25 | 1.02 | 1.28 |
| 7 Days Ago | 0.22 | 0.25 | 1.02 | 1.28 |
| 30 Days Ago | 0.23 | 0.27 | 1.09 | 1.38 |
| 60 Days Ago | 0.21 | 0.25 | 0.99 | 1.39 |
| 90 Days Ago | 0.23 | 0.25 | 1.01 | 1.73 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CORT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 57.10% | -- | -- | 1.50% |
| Next Qtr. | 0.00% | -- | -- | 11.40% |
| Current Year | 8.50% | -- | -- | 5.20% |
| Next Year | 25.50% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -41.40% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 4.84% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/23/2024 |
| Maintains | Truist Securities: Buy to Buy | 2/16/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/2/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 12/13/2023 |
| Upgrade | Truist Securities: Hold to Buy | 11/6/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/2/2023 |
Related Tickers
DAWN Day One Biopharmaceuticals, Inc.
13.44
-11.54%
JANX Janux Therapeutics, Inc.
46.62
-3.31%
CYTK Cytokinetics, Incorporated
65.14
-2.51%
IMVT Immunovant, Inc.
27.62
-4.10%
BHVN Biohaven Ltd.
37.85
-2.26%
APGE Apogee Therapeutics, Inc.
45.47
-2.30%
MLTX MoonLake Immunotherapeutics
42.59
+0.38%
ANRO Alto Neuroscience, Inc.
13.91
-2.08%
APLS Apellis Pharmaceuticals, Inc.
47.43
-5.01%
INCY Incyte Corporation
50.53
-2.35%